Industry Verticals »

All Categories

Insights »

About TMR »

Osteoporosis Drugs Market

Osteoporosis Drugs Market (By Drug Class Bisphosphonates, Calcitonin, RANK Ligand Inhibitors, Parathyroid Hormone Therapy (PTH), Selective Estrogen Receptor Modulators (SERMs), Others Estrogen therapy and vitamin D and Calcium) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends & Forecast 2019-2027

  • According to Transparency Market Research’s latest report on the global osteoporosis drugs market for the historical period 2017-2018 and forecast period 2019-2027, rising prevalence of osteoporosis, growing aging population which is more prone to osteoporosis, and introduction of new therapies are projected to drive the global Osteoporosis Drugs market during the forecast period
  • According to the report, the global osteoporosis drugs market was valued at US$ 11.5 Bn in 2018 and is anticipated to contract at a CAGR of 0.3% from 2019 to 2027

global osteoporosis drugs market

High Incidence and prevalence of osteoporosis coupled with growth in geriatric population: Key Driver

  • Rising prevalence of osteoporosis is considered an important driver of the market, as more patients would increase demand for the drugs. Moreover, due to absence of any substantial substitute, such as surgery, demand for osteoporosis drugs is increasing constantly.
  • For instance, according to International Osteoporosis Foundation, Osteoporosis causes more than 8.9 million fractures annually, resulting in an osteoporotic fracture every 3 seconds and also it is estimated to affect 200 million women globally.
  • Furthermore, rising geriatric population is considered an important factor for growth of the market in coming years. Individuals above 50 years of age are at the greatest risk of developing osteoporosis and related fractures due to hormonal changes.
  • The number of people aged 65 years and above is projected to increase from 524 million in 2010 to approximately 1.5 billion in 2050. This high proportion of geriatric population is more prone to osteoporosis.

Patent expiry of blockbuster drugs and dynamic changes in pricing due to generics restrain market growth

  • Patent expiry and loss of exclusivity are considered major restraints of the osteoporosis drugs market. As the generic equivalents of branded drugs are manufactured and marketed at 1/10th of the price of the original branded drug, loss of patent exclusivity of a branded drug results in drastic revenue reduction amounting to almost 35% - 40% in the first year.
  • This low cost of generics results in higher consumption, although, generic drugs are not able to achieve or exceed the overall sales of the branded formulation.

Global Osteoporosis Drugs Market: North America Dominated the global market

  • On the basis of region, the osteoporosis drugs market is segmented as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.
  • North America region dominated the global market owing to the presence of large number of osteoporosis patients, world-class medical infrastructure, rising awareness about the disease and its treatment and proper utilization of technologically sound devices for diagnosis purpose.
  • However, Asia-Pacific region is considered as the most promising market during the forecast period from 2014 to 2020. The growth is mainly attributed to factors such as steadily increasing incidence rate of osteoporosis, increasing medical expenditure, increased healthcare awareness towards diagnosis and treatment of osteoporosis and dietary habits and lack of nutritious foods.

Global Osteoporosis Drugs Market: Competitive Landscape

  • This report profiles major players in the global osteoporosis drugs market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global osteoporosis drugs market is highly fragmented, with the presence of a number of international as well as regional players
  • Leading players operating in the global Osteoporosis Drugs market are
    • Eli Lilly and Company
    • Pfizer, Inc.
    • Amgen, Inc.
    • Merck & Co., Inc.
    • Radius Health, Inc.
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Novo Nordisk A/S
    • F. Hoffmann-La Roche Ltd.
    • UCB S.A.
    • Mylan N.V.
    • Apotex Inc.

Global Osteoporosis Drugs Market: Key Developments

Key players in the global osteoporosis drugs market are engaged in regulatory approvals, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global osteoporosis drugs market. A few expansion strategies adopted by players operating in the global Osteoporosis Drugs market are:

  • On April 09, 2019, Amgen Inc. has got U.S. FDA approval for its drug EVENITY (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk for fracture.
  • On August 05, 2019, Radius Health, Inc., Initiated the Phase 3 wearABLe Study of Abaloparatide-Patch in Postmenopausal Osteoporosis Patients at High Risk for Fracture.

The report on the global Osteoporosis Drugs market discussed individual strategies, followed by company profiles of manufacturers of Osteoporosis Drugs. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global Osteoporosis Drugs market.

Frequently Asked Questions

What is the total market worth of osteoporosis drugs market?

Osteoporosis drugs market is expected to reach US$ 11.7 bn by 2027

What is the anticipated CAGR of the osteoporosis drugs market in the forecast period?

Osteoporosis drugs market is anticipated to contract at a CAGR of 0.3% from 2019 to 2027

What are the key driving factors for the growth of the osteoporosis drugs market?

Osteoporosis drugs market is driven by growing prevalence of osteoporosis across globe

Which region is expected to project the highest market share in the global osteoporosis drugs market?

North America accounted for a major share of the global osteoporosis drugs market owing to the presence of large number of osteoporosis patients

Who are the key players in the osteoporosis drugs market?

Key players operating in the global Osteoporosis Drugs market include Eli Lilly and Company, Pfizer, Inc., Amgen, Inc., Merck & Co., Inc., Radius Health, Inc.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Osteoporosis Drugs Market

4. Market Overview

    4.1. Introduction

        4.1.1. Drug ClassDefinition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Osteoporosis Drugs Market Analysis and Forecasts, 2017-2027

        4.4.1. Market Revenue Projections (US$ Mn)

5. Market Outlook

    5.1. Pipeline Analysis

    5.2. Value Chain Analysis

    5.3. Key Mergers, Acquisition, and Strategic Partnerships

    5.4. Osteoporosis Prevalence Globally with Key regions and Countries

6. Global Osteoporosis Drugs Market Analysis and Forecasts, By Drug Class

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast By Drug Type, 2017-2027

        6.3.1. Bisphosphonates

        6.3.2. Calcitonin

        6.3.3. RANK Ligand Inhibitors

        6.3.4. Selective Estrogen Receptor Modulators (SERMs)

        6.3.5. Parathyroid Hormone Therapy (PTH) Drugs

        6.3.6. Sclerostin Inhibitors

        6.3.7. Others

    6.4. Market Attractiveness By Drug Class

7. Global Osteoporosis Drugs Market Analysis and Forecasts, By Region

    7.1. Key Findings

    7.2. Market Value Forecast By Region

        7.2.1. North America

        7.2.2. Europe

        7.2.3. Asia Pacific

        7.2.4. Latin America

        7.2.5. Middle East & Africa

    7.3. Market Attractiveness By Country/Region

8. North America Osteoporosis Drugs Market Analysis and Forecast

    8.1. Introduction

        8.1.1. Key Findings

    8.2. Market Value Forecast By Drug Type, 2017-2027

        8.2.1. Bisphosphonates

        8.2.2. Calcitonin

        8.2.3. RANK Ligand Inhibitors

        8.2.4. Selective Estrogen Receptor Modulators (SERMs)

        8.2.5. Parathyroid Hormone Therapy (PTH) Drugs

        8.2.6. Sclerostin Inhibitors

        8.2.7. Others

    8.3. Market Value Forecast By Country, 2017-2027

        8.3.1. U.S.

        8.3.2. Canada

    8.4. Market Attractiveness Analysis

        8.4.1. By Drug Class

        8.4.2. By Country

9. Europe Osteoporosis Drugs Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. Market Value Forecast By Drug Type, 2017-2027

        9.2.1. Bisphosphonates

        9.2.2. Calcitonin

        9.2.3. RANK Ligand Inhibitors

        9.2.4. Selective Estrogen Receptor Modulators (SERMs)

        9.2.5. Parathyroid Hormone Therapy (PTH) Drugs

        9.2.6. Sclerostin Inhibitors

        9.2.7. Others

    9.3. Market Value Forecast By Country, 2017-2027

        9.3.1. Germany

        9.3.2. U.K.

        9.3.2. France

        9.3.2. Italy

        9.3.2. Spain

        9.3.2. Rest of Europe

    9.4. Market Attractiveness Analysis

        9.4.1. By Drug Class

        9.4.2. By Country

10. Asia Pacific Osteoporosis Drugs Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast By Drug Type, 2017-2027

        10.2.1. Bisphosphonates

        10.2.2. Calcitonin

        10.2.3. RANK Ligand Inhibitors

        10.2.4. Selective Estrogen Receptor Modulators (SERMs)

        10.2.5. Parathyroid Hormone Therapy (PTH) Drugs

        10.2.6. Sclerostin Inhibitors

        10.2.7. Others

    10.3. Market Value Forecast By Country, 2017-2027

        10.3.1. China

        10.3.2. Japan

        10.3.2. India

        10.3.2. Australia & New Zealand

        10.3.2. Rest of Asia Pacific

    10.4. Market Attractiveness Analysis

        10.4.1. By Drug Class

        10.4.2. By Country

11. Latin America Osteoporosis Drugs Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast By Drug Type, 2017-2027

        11.2.1. Bisphosphonates

        11.2.2. Calcitonin

        11.2.3. RANK Ligand Inhibitors

        11.2.4. Selective Estrogen Receptor Modulators (SERMs)

        11.2.5. Parathyroid Hormone Therapy (PTH) Drugs

        11.2.6. Sclerostin Inhibitors

        11.2.7. Others

    11.3. Market Value Forecast By Country, 2017-2027

        11.3.1. Brazil

        11.3.2. Mexico

        11.3.2. Rest of Latin America

    11.4. Market Attractiveness Analysis

        11.4.1. By Drug Class

        11.4.2. By Country

12. Middle East & Africa Osteoporosis Drugs Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast By Drug Type, 2017-2027

        12.2.1. Bisphosphonates

        12.2.2. Calcitonin

        12.2.3. RANK Ligand Inhibitors

        12.2.4. Selective Estrogen Receptor Modulators (SERMs)

        12.2.5. Parathyroid Hormone Therapy (PTH) Drugs

        12.2.6. Sclerostin Inhibitors

        12.2.7. Others

    12.3. Market Value Forecast By Country, 2017-2027

        12.3.1. GCC Countries

        12.3.2. South Africa

        12.3.2. Rest of Middle East & Africa

    12.4. Market Attractiveness Analysis

        12.4.1. By Drug Class

        12.4.2. By Country

13. Competition Landscape

    13.1. Market Player - Competition Matrix (By Tier and Size of companies)

    13.2. Market Share/Poisition Analysis By Company (2018)

    13.3. Company Profiles

        13.3.1. Eli Lilly and Company

            13.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.1.2. Company Financials

            13.3.1.3. Growth Strategies

            13.3.1.4. SWOT Analysis

        13.3.2. Amgen, Inc.

            13.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.2.2. Company Financials

            13.3.2.3. Growth Strategies

            13.3.2.4. SWOT Analysis

        13.3.3. F.Hoffmann-La Roche Ltd.

            13.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.3.2. Company Financials

            13.3.3.3. Growth Strategies

            13.3.3.4. SWOT Analysis

        13.3.4. Merck & Co., Inc.

            13.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.4.2. Company Financials

            13.3.4.3. Growth Strategies

            13.3.4.4. SWOT Analysis

        13.3.5. Novartis AG

            13.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.5.2. Company Financials

            13.3.5.3. Growth Strategies

            13.3.5.4. SWOT Analysis

        13.3.6. Novo Nordisk A/S

            13.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.6.2. Company Financials

            13.3.6.3. Growth Strategies

            13.3.6.4. SWOT Analysis

        13.3.7. Teva Pharmaceutical Industries Ltd.

            13.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.7.2. Company Financials

            13.3.7.3. Growth Strategies

            13.3.7.4. SWOT Analysis

        13.3.8. Pfizer, Inc.

            13.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.8.2. Company Financials

            13.3.8.3. Growth Strategies

            13.3.8.4. SWOT Analysis

        13.3.9. Radius Health, Inc.

            13.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.9.2. Company Financials

            13.3.9.3. Growth Strategies

            13.3.9.4. SWOT Analysis

        13.3.10. Apotex Inc.

            13.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.10.2. Company Financials

            13.3.10.3. Growth Strategies

            13.3.10.4. SWOT Analysis

List of Table

Table 01: Pipeline Analysis

Table 02: Key Mergers, Acquisition, and Strategic Partnerships

Table 03: Global Osteoporosis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027

Table 04: Global Osteoporosis Drugs Market Value (US$ Mn) Forecast, by Region, 2017-2027

Table 05: North America Osteoporosis Drugs Market Value (US$ Mn) Forecast, by Country, 2017-2027

Table 06: North America Osteoporosis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027

Table 07: Europe Osteoporosis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027

Table 08: Europe Osteoporosis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027

Table 09: Asia Pacific Osteoporosis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027

Table 10: Asia Pacific Osteoporosis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027

Table 11: Latin America Osteoporosis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027

Table 12: Latin America Osteoporosis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027

Table 13: Middle East & Africa Osteoporosis Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027

Table 14: Middle East & Africa Osteoporosis Drugs Market Value (US$ Mn) Forecast, by Drug Class, 2017-2027

List of Figure

Figure 01: Global Osteoporosis Drugs Market Size (US$ Mn) and Distribution, by Region, 2018 and 2027

Figure 02: Global Osteoporosis Drugs Market Value (US$ Mn), by Drug Class, 2018 (A)

Figure 03: Global Osteoporosis Drugs Market, Top 3 Trends, 2018

Figure 04: Market Overview

Figure 05: Global Osteoporosis Drugs Market Value (US$ Mn) Forecast, 2017-2027

Figure 06: Global Osteoporosis Drugs Market Value Share, by Drug Class (2018)

Figure 07: Global Osteoporosis Drugs Market Value Share, by Region(2018)

Figure 08: Global Osteoporosis Drugs Market Value Share Analysis, by Drug Class, 2018 and 2027

Figure 09: Market Opportunity Map, by Drug Class

Figure 10: Snapshot, Value Chain Analysis

Figure 11: Snapshot, Osteoporosis Prevalence Globally

Figure 12: Global Osteoporosis Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Bisphosphonates, 2017-2027

Figure 13: Global Osteoporosis Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Calcitonin, 2017-2027

Figure 14: Global Osteoporosis Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by RANK Ligand Inhibitor, 2017-2027

Figure 15: Global Osteoporosis Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Selective Estrogen Receptor Modulators (SERMs) , 2017-2027

Figure 16: Global Osteoporosis Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Parathyroid Hormone Therapy (PTH) Drugs , 2017-2027

Figure 17: Global Osteoporosis Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Sclerostin Inhibitors, 2017-2027

Figure 18: Global Osteoporosis Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017-2027

Figure 19: Global Osteoporosis Drugs Market Attractiveness Analysis, by Drug Class 2019-2027

Figure 20: Global Osteoporosis Drugs Market Attractiveness Analysis, by Region, 2019-2027

Figure 21: North America Osteoporosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2027

Figure 22: North America Osteoporosis Drugs Market Value Share, by Country, 2018 and 2027

Figure 23: North America Osteoporosis Drugs Market Attractiveness, by Country, 2019-2027

Figure 24: North America Osteoporosis Drugs Market Value Share, by Drug Class, 2018 and 2027

Figure 25: North America Osteoporosis Drugs Market Attractiveness, by Drug Class, 2019-2027

Figure 26: Europe Osteoporosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2027

Figure 27: Europe Osteoporosis Drugs Market Value Share, by Country, 2018 and 2027

Figure 28: Europe Osteoporosis Drugs Market Attractiveness, by Country, 2019-2027

Figure 29: Europe Osteoporosis Drugs Market Value Share, by Drug Class, 2018 and 2027

Figure 30: Europe Osteoporosis Drugs Market Attractiveness, by Drug Class, 2019-2027

Figure 31: Asia Pacific Osteoporosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2027

Figure 32: Asia Pacific Osteoporosis Drugs Market Value Share, by Country, 2018 and 2027

Figure 33: Asia Pacific Osteoporosis Drugs Market Attractiveness, by Country, 2019-2027

Figure 34: Asia Pacific Osteoporosis Drugs Market Value Share, by Drug Class, 2018 and 2027

Figure 35: Asia Pacific Osteoporosis Drugs Market Attractiveness, by Drug Class, 2019-2027

Figure 36: Latin America Osteoporosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2027

Figure 37: Latin America Osteoporosis Drugs Market Value Share, by Country, 2018 and 2027

Figure 38: Latin America Osteoporosis Drugs Market Attractiveness, by Country, 2019-2027

Figure 39: Latin America Osteoporosis Drugs Market Value Share, by Drug Class, 2018 and 2027

Figure 40: Latin America Osteoporosis Drugs Market Attractiveness, by Drug Class, 2019-2027

Figure 41: Middle East & Africa Osteoporosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2027

Figure 42: Middle East & Africa Osteoporosis Drugs Market Value Share, by Country, 2018 and 2027

Figure 43: Middle East & Africa Osteoporosis Drugs Market Attractiveness, by Country, 2019-2027

Figure 44: Middle East & Africa Osteoporosis Drugs Market Value Share, by Drug Class, 2018 and 2027

Figure 45: Middle East & Africa Osteoporosis Drugs Market Attractiveness, by Drug Class, 2019-2027

Figure 46: Market Position/Ranking Analysis, 2018, by Tier and Size of the Company

Figure 47: Eli Lilly and Company, Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2018

Figure 48: Eli Lilly and Company, R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2018

Figure 49: Eli Lilly and Company, Breakdown of Net Sales, by Region, 2018

Figure 50: Eli Lilly and Company, Breakdown of Net Sales, by Business Segment, 2018

Figure 51: Amgen, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2018

Figure 52: Amgen, Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2018

Figure 53: Amgen, Inc., Breakdown of Net Sales, by Region, 2018

Figure 54: Amgen, Inc., Breakdown of Net Sales, by Business Segment, 2018

Figure 55: F.Hoffmann-La Roche Ltd., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2018

Figure 56: F.Hoffmann-La Roche Ltd., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2018

Figure 57: F.Hoffmann-La Roche Ltd., Breakdown of Net Sales, by Region, 2018

Figure 58: F.Hoffmann-La Roche Ltd., Breakdown of Net Sales, by Business Segment, 2018

Figure 59: Merck & Co., Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2018

Figure 60: Merck & Co., Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2018

Figure 61: Merck & Co., Inc., Breakdown of Net Sales, by Region, 2018

Figure 62: Merck & Co., Inc., Breakdown of Net Sales, by Business Segment, 2018

Figure 63: Novartis AG, Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2018

Figure 64: Novartis AG, R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2018

Figure 65: Novartis AG, Breakdown of Net Sales, by Region, 2018

Figure 66: Novartis AG, Breakdown of Net Sales, by Business Segment, 2018

Figure 67: Novo Nordisk A/S, Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2018

Figure 68: Novo Nordisk A/S, R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2018

Figure 69: Novo Nordisk A/S, Breakdown of Net Sales, by Region, 2018

Figure 70: Novo Nordisk A/S, Breakdown of Net Sales, by Business Segment, 2018

Figure 71: Teva Pharmaceutical Industries Ltd., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2018

Figure 72: Teva Pharmaceutical Industries Ltd., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2018

Figure 73: Teva Pharmaceutical Industries Ltd., Breakdown of Net Sales, by Region, 2018

Figure 74: Teva Pharmaceutical Industries Ltd., Breakdown of Net Sales, by Business Segment, 2018

Figure 75: Pfizer, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2018

Figure 76: Pfizer, Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2018

Figure 77: Pfizer, Inc., Breakdown of Net Sales, by Region, 2018

Figure 78: Pfizer, Inc., Breakdown of Net Sales, by Business Segment, 2018

Figure 79: Radius Health, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2018

Figure 80: Radius Health, Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2018

Figure 81: Radius Health, Inc., Breakdown of Net Sales, by Region, 2018

Figure 82: Radius Health, Inc., Breakdown of Net Sales, by Business Segment, 2018

Figure 83: Apotex Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2018

Figure 84: Apotex Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2018

Figure 85: Apotex Inc., Breakdown of Net Sales, by Region, 2018

Figure 86: Apotex Inc., Breakdown of Net Sales, by Business Segment, 2018

Copyright © Transparency Market Research, Inc. All Rights reserved

Osteoporosis Drugs Market

Schedule a Call